RxDoctor Payments DataLook up a doctor →

Sam Zand, DO

Psychiatry · Las Vegas, NVNPI 1528485570

Payments from drug & device makers

$410,217in general payments, 2019–2025

Across 609 payments — averaging $673.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$160K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$71K
  • Otsuka America Pharmaceutical, Inc.$47K
  • AbbVie$45K
  • Axsome Therapeutics, Inc.$37K
  • Neuronetics, Inc.$26K
  • plus $24K from 12 others

What the payments were for

  • Consulting fees$17,7504%
  • Speaking & faculty fees$321,24578%
  • Travel & lodging$54,90313%
  • Food & beverage$16,1954%
  • Education$1230%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$410,217 in reported general payments places this provider in the 95th percentile of 243 psychiatry providers in Nevada.

See all psychiatry providers in Nevada

Medicare billing

Part B allowed, 2024
$89,861
Medicare patients
43
Services billed
949

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole14$19,804
TrintellixVortioxetine Hydrobromide19$3,282
Alprazolam ErAlprazolam13$640
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine14$630
Hydroxyzine Hcl19$488
Gabapentin56$391
Zolpidem Tartrate ErZolpidem Tartrate13$386
Lorazepam14$371
Quetiapine Fumarate34$311
Duloxetine Hcl11$228
Quetiapine Fumarate ErQuetiapine Fumarate12$205
Risperidone15$162
Venlafaxine Hcl ErVenlafaxine Hcl11$162
Bupropion XlBupropion Hcl14$161
Trazodone Hcl21$107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$46,946$19,80414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 243 psychiatry providers in Nevada.

Other psychiatry in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →